Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLOFITAMAB-GXBM Cause C-reactive protein increased? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of C-reactive protein increased have been filed in association with GLOFITAMAB-GXBM. This represents 1.4% of all adverse event reports for GLOFITAMAB-GXBM.

7
Reports of C-reactive protein increased with GLOFITAMAB-GXBM
1.4%
of all GLOFITAMAB-GXBM reports
1
Deaths
4
Hospitalizations

How Dangerous Is C-reactive protein increased From GLOFITAMAB-GXBM?

Of the 7 reports, 1 (14.3%) resulted in death, 4 (57.1%) required hospitalization.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLOFITAMAB-GXBM. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does GLOFITAMAB-GXBM Cause?

Cytokine release syndrome (107) Disease progression (68) Off label use (68) Death (67) Pyrexia (45) No adverse event (28) Immune effector cell-associated neurotoxicity syndrome (25) Infection (20) Pneumonia (14) Condition aggravated (12)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which GLOFITAMAB-GXBM Alternatives Have Lower C-reactive protein increased Risk?

GLOFITAMAB-GXBM vs GLUCAGON GLOFITAMAB-GXBM vs GLUCAGON\GLUCAGON\WATER GLOFITAMAB-GXBM vs GLUCARPIDASE GLOFITAMAB-GXBM vs GLUCOPHAGE GLOFITAMAB-GXBM vs GLUCOSAMINE

Related Pages

GLOFITAMAB-GXBM Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased GLOFITAMAB-GXBM Demographics